

#### IV. Remarks and Conclusion

Claims 2, 7, 11, 13, 15, and 16 are presently pending. Claims 14 and 17 have been cancelled, without prejudice or disclaimer. The cancellation was not made for any reason related to patentability and no estoppel should result.

In response to the rejections under 35 USC §112, 1<sup>st</sup> ¶, Applicants have amended the Claims to recite mucosal administration. Support for the amendment can be found in the paragraph bridging pages 11 and 12. The Examiner indicated that such nasal administration was enabled. Accordingly, Applicants respectfully request reconsideration of the rejection in light of this response.

Claims 14 and 17 have been cancelled.

The application is believed in a condition for allowance and Applicants respectfully request such action. Please call the below undersigned attorney for any assistance in securing allowance of this application or if the Examiner feels that an interview would further the prosecution of this case. Please charge deposit account number 02-2334 for any required fees and to credit any credits.

Date:

3/05/04

Sincerely,



William P. Ramey, III  
Reg. No. 44,295

Akzo Nobel Pharma Patent Department  
Intervet, Inc.  
405 State Street  
Millsboro, DE 19966  
(302) 933-4034 telephone  
(302) 934-4305 facsimile